[Annual Report on Form 10-K Year Ended December 31, 2015 TABLE OF CONTENTS PART I Item 1. Business 3 Item 1A. Risk Factors 24 Item 1B. Unresolved Staff Comments 45 Item 2. Properties 45 Item 3. Legal Proceedings 46 Item 4. Mine Safety Disclosures 48 PART II Item 5. 49 Item 6. Selected Financial Data 50 Item 7. Management’s Discussion] [CHINA BIOLOGIC PRODUCTS, INC. The subsidiaries of China Biologic Products, Inc. are as follows: Jurisdiction of Name Incorporation or Organization Ownership Interest Taibang Biological Ltd. BVI 100.0% Taibang Holdings (Hong Kong) Limited HK 100.0% Taibang Biotech (Shandong) Co., Ltd. Shandong PRC 100.0% Taibang (Beijing) Pharmaceutical Research Institute Co., Ltd. Beijing PRC 100.0% Shandong Taibang Biological Products Co., Ltd. Shandong PRC] [Consent of Independent Registered Public Accounting Firm The Board of Directors We consent to the incorporation by reference in the registration statement (No. 333-204761) on Form S-3 and the registration statement (No. 333-151263) on Form S-8 of China Biologic Products, Inc. of our reports dated February 25, 2016, with respect to the consolidated balance sheets of China Biologic Products, Inc.] [CERTIFICATIONS I, David (Xiaoying) Gao, certify that: 1. I have reviewed this annual report on Form 10-K of China Biologic Products, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such] [CERTIFICATIONS I, Ming Yang, certify that: 1. I have reviewed this annual report on Form 10-K of China Biologic Products, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements] [2. Information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company. th David (Xiaoying) Gao Chief Executive Officer] [2. Information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company. th Ming Yang Chief Financial Officer (Principal Financial and Accounting Officer)]

[CHINA BIOLOGIC PRODUCTS, INC. AMENDED AND RESTATED DIRECTOR AGREEMENT Agreement Company Mr. David Li Director THIS AGREEMENT (this “ BACKGROUND Original Agreement The Director and the Company entered into a director agreement (the “ The Director and the Company desire to enter into this Agreement to amend and restate the Original Agreement in its entirety. AGREEMENT In consideration for the] [FOR RELEASE February 25, 2016 China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2015 4Q15 Total Sales Up 22.6% with Non-GAAP Net Income Up 44.5% YoY in RMB terms, or Up 17.8% YoY to $68.3 Million and 38.8% YoY to $20.4 Million in USD terms, respectively FY15 Total Sales Up 23.4% with Non-GAAP Net Income Up] []

[China Biologic to Attend the 34th Annual J.P. Morgan Healthcare Conference BEIJING, China – January 4, 2016 – Management will present at the conference on Wednesday, January 13, 2016 at 10:30am Pacific Time. For additional information or interest in meeting with management, please contact your J.P. Morgan institutional sales representative. About China Biologic Products, Inc. China Biologic Products, Inc. (NASDAQ:] [34 th Annual J.P . Morgan Healthcare Conference January 2016 China Biologic Products, Inc. (NASDAQ: CBPO) Creating Miracles in Life Capital Structure Price: $142.46 (12/31/2015 ) Market Capitalization: $3.8 billion 52 - Week Range: $64.36 - $143.21 Shares Outstanding : 26.5 mm Selected 9M15 Financials Revenue: $228.2 mm, up 23.2% y - o - y Gross Profit: $148.7 mm, up] []